ArticleNature nanotechnology2024
Polymersomes with splenic avidity target red pulp myeloid cells for cancer immunotherapy.
Abstract read
In one paragraph
Article in Nature nanotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Unlocking the brain: Biodistribution insights into tween 80 nanoliposomes in healthy brains.International journal of pharmaceutics: X · 2026Article
- Anisotropic Masked Mycobacterium Potentiates Amplified Antitumor Trained Immunity via Spleen Targeting and Myelopoiesis Conversion.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Engineering Morphological Anisotropy to Control the In Vivo Transport Dynamics, Clearance, and Biodistribution of Silica Nanocarriers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Photoresponsive Discoidal Polymersomes With Tracelessly Crosslinkable Bilayers for Intracellular Drug Delivery.Angewandte Chemie (International ed. in English) · 2026Article
- Integrated theranostic nanoplatform empowers precision cancer care via radionuclide-labeled NIR-II aggregation-induced emission luminogens.Nature communications · 2026Article
- [EJNMMI research · 2026Article
- Therapeutic strategies for ischemic heart disease with natural product-based nanomedicines.Journal of nanobiotechnology · 2026Review
- Architecture-Encoded Degradation Kinetics and Pathways through the Shape and Size of Polymeric Vesicles.Journal of the American Chemical Society · 2026Article
- Polymer-mRNA complexes for monocyte-trafficked, lymph node-targeted cancer vaccination.Nature biomedical engineering · 2026Article
- Monocyte/macrophage-mediated trained immunity in disease prevention and immunotherapy.Bioactive materials · 2026Review
- Tailored Organogel Systems for Optimized Pesticide Delivery: Mechanistic Insights and Agricultural Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Illumination of Targeting Nanotherapeutics with Precision Eyes: From Optical to Radio-nanotheranostics.Theranostics · 2026Review
- ROS-responsive cellular vesicles with ferroptosis-targeting siACMSD delivery for acute kidney injury therapy.Theranostics · 2026Article
- Review
- Advanced Pharmaceutical Nanotechnologies Applied for Chinese Herbal Medicines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Drug-loaded nanoparticles induce immunogenic cell death and efficiently target cells from glioblastoma patients.Nanomedicine (London, England) · 2025Article
- Design and Applications of Polymersomes for Oral Drug Administration.ACS applied materials & interfaces · 2025Review
- β-1,3 Glucan Microparticles & Nanoparticles: Fabrication Methods & Applications in Immunomodulation & Targeted Drug Delivery.Advanced healthcare materials · 2025Review
- Polymeric Nanoarchitectures: Advanced Cargo Systems for Biological Applications.Macromolecular bioscience · 2025Review
- Mitochondrial transplantation for ischemic heart disease.Nature nanotechnology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Annelies C Wauters *Bio-Organic Chemistry, Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.ORCID http://orcid.org/0000-0001-5136-3889
Jari F Scheerstra *Bio-Organic Chemistry, Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.ORCID http://orcid.org/0000-0003-0129-5464
Mandy M T van Leent *BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-9747-1022
Abraham J P Teunissen *BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-0401-8262
Bram PriemBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Thijs J BeldmanDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
Nils RotherDepartment of Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0001-5129-3956
Raphaël DuivenvoordenBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-1446-8336
Geoffrey PrévotBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jazz MunitzBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Yohana C TonerDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0001-5309-6366
Jeroen DeckersDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
Yuri van ElsasDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0009-0002-2985-3368
Patricia Mora-RaimundoThe Luis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion, Haifa, Israel.
Gal ChenThe Luis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion, Haifa, Israel.
Sheqouia A NautaBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Anna Vera D VerschuurBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Arjan W GriffioenDepartment of Medical Oncology (NA Angiogenesis Laboratory), Amsterdam University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands.
David P SchrijverLaboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.ORCID http://orcid.org/0000-0002-2177-4836
Tom AnbergenDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0002-7155-7709
Yudong LiBio-Organic Chemistry, Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.ORCID http://orcid.org/0009-0006-9140-5733
Hanglong WuBio-Organic Chemistry, Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.
Alexander F MasonBio-Organic Chemistry, Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.ORCID http://orcid.org/0000-0002-2847-0253
Marleen H M E van StevendaalBio-Organic Chemistry, Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.
Ewelina KluzaLaboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.ORCID http://orcid.org/0000-0002-7040-0427
Richard A J PostDepartment of Mathematics and Computer Science, Institute of Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.ORCID http://orcid.org/0000-0001-6110-7467
Leo A B JoostenDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0001-6166-9830
Mihai G NeteaDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.ORCID http://orcid.org/0000-0003-2421-6052
Claudia CalcagnoBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Zahi A FayadBioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-3439-7347
Roy van der MeelLaboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.ORCID http://orcid.org/0000-0002-2200-7946
Avi SchroederThe Luis Family Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion, Haifa, Israel.ORCID http://orcid.org/0000-0003-2571-5937
Loai K E A AbdelmohsenBio-Organic Chemistry, Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands. l.k.e.a.abdelmohsen@tue.nl.ORCID http://orcid.org/0000-0002-0094-1893
Willem J M MulderDepartment of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands. willem.mulder@radboudumc.nl.ORCID http://orcid.org/0000-0001-8665-3878
Jan C M van HestBio-Organic Chemistry, Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands. j.c.m.v.hest@tue.nl.ORCID http://orcid.org/0000-0001-7973-2404
Funding
Translational imaging and nanomedicine in inflammatory atherosclerosisP01HL131478 · NHLBI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Zahi A. Fayad · 2017 to 2026
$24.3MUsing trained immunity-inhibiting nanobiologics to achieve tolerance of heart allografts in non-human primatesP01AI168258 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Zahi A. Fayad, Joren C Madsen · 2023 to 2026
$14.7MAzrieli Foundation postdoctoral fellowshipEC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) ERC Advanced Grant (#833247)EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) ERC Advanced Grant (Artisym 694120)EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) ERC, Smart Nanoparticles, 101089009NHLBI NIH HHS P01 HL131478NIAID NIH HHS P01 AI168258Rothschild Caesarea Foundation Baroness Ariane de Rothschild Women Doctoral Program
Abstract
Regulating innate immunity is an emerging approach to improve cancer immunotherapy. Such regulation requires engaging myeloid cells by delivering immunomodulatory compounds to hematopoietic organs, including the spleen. Here we present a polymersome-based nanocarrier with splenic avidity and propensity for red pulp myeloid cell uptake. We characterized the in vivo behaviour of four chemically identical yet topologically different polymersomes by in vivo positron emission tomography imaging and innovative flow and mass cytometry techniques. Upon intravenous administration, relatively large and spherical polymersomes accumulated rapidly in the spleen and efficiently targeted myeloid cells in the splenic red pulp. When loaded with β-glucan, intravenously administered polymersomes significantly reduced tumour growth in a mouse melanoma model. We initiated our nanotherapeutic's clinical translation with a biodistribution study in non-human primates, which revealed that the platform's splenic avidity is preserved across species.
Indexed as
ImmunotherapyMyeloid CellsSpleenAnimalsCell Line, TumorHumansMelanomaMelanoma, ExperimentalMiceMice, Inbred C57BLPolymersTissue DistributionPolymers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.